- Home
- URGN vs ACEL Comparison
URGN vs ACEL Comparison
Compare URGN & ACEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- ACEL
- Stock Information
- Founded
- URGN 2004
- ACEL 2009
- Country
- URGN United States
- ACEL United States
- Employees
- URGN N/A
- ACEL N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- ACEL Services-Misc. Amusement & Recreation
- Sector
- URGN Health Care
- ACEL Consumer Discretionary
- Exchange
- URGN Nasdaq
- ACEL Nasdaq
- Market Cap
- URGN 904.0M
- ACEL 934.8M
- IPO Year
- URGN 2017
- ACEL N/A
- Fundamental
- Price
- URGN $18.94
- ACEL $11.15
- Analyst Decision
- URGN Strong Buy
- ACEL Buy
- Analyst Count
- URGN 8
- ACEL 1
- Target Price
- URGN $28.50
- ACEL $16.00
- AVG Volume (30 Days)
- URGN 1.1M
- ACEL 326.6K
- Earning Date
- URGN 11-05-2025
- ACEL 10-29-2025
- Dividend Yield
- URGN N/A
- ACEL N/A
- EPS Growth
- URGN N/A
- ACEL N/A
- EPS
- URGN N/A
- ACEL 0.40
- Revenue
- URGN $94,238,000.00
- ACEL $1,279,563,000.00
- Revenue This Year
- URGN $35.60
- ACEL $9.99
- Revenue Next Year
- URGN $129.54
- ACEL $5.17
- P/E Ratio
- URGN N/A
- ACEL $28.42
- Revenue Growth
- URGN 10.85
- ACEL 7.00
- 52 Week Low
- URGN $3.42
- ACEL $9.02
- 52 Week High
- URGN $21.71
- ACEL $13.28
- Technical
- Relative Strength Index (RSI)
- URGN 49.18
- ACEL 44.06
- Support Level
- URGN $18.45
- ACEL $10.99
- Resistance Level
- URGN $21.71
- ACEL $11.41
- Average True Range (ATR)
- URGN 1.18
- ACEL 0.25
- MACD
- URGN -0.17
- ACEL 0.00
- Stochastic Oscillator
- URGN 20.90
- ACEL 22.42
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About ACEL Accel Entertainment Inc.
Accel Entertainment Inc is a distributed gaming and local entertainment operator in the United States. It is engaged in the installation, maintenance, operation, and servicing of gaming terminals and related equipment, redemption devices that disburse winnings and contain automated teller machine (ATM) functionality, and amusement devices in authorized non-casino locations such as restaurants, bars, taverns, convenience stores, liquor stores, truck stops, and grocery stores. The Company also operates stand-alone ATMs in gaming and non-gaming locations. It generates revenue from Net gaming, Amusement, Manufacturing, ATM fees, and others.